BAX - Baxter International Inc.
| Previous Close | 77.69 |
| Open | 77.85 |
| Bid | 0.00 x 45100 |
| Ask | 0.00 x 1200 |
| Day's Range | 77.32 - 77.92 |
| 52 Week Range | 60.78 - 78.38 |
| Volume | 4,064,285 |
| Avg. Volume | 2,713,633 |
| Market Cap | 41.336B |
| Beta | 1.09 |
| PE Ratio (TTM) | 47.12 |
| EPS (TTM) | 1.64 |
| Earnings Date | Oct 31, 2018 |
| Forward Dividend & Yield | 0.76 (0.98%) |
| Ex-Dividend Date | 2018-08-30 |
| 1y Target Est | 79.62 |
Markit•2 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Business Wire•3 days ago
Baxter to Host Third Quarter 2018 Financial Results Conference Call for Investors
Baxter International Inc. (BAX), a leading global medical products company, will host a conference call to discuss its third quarter 2018 financial results on Wednesday, October 31, 2018, at 7:30 a.m. Central Time. To access the call, dial (844) 886-1929 (domestic) or (225) 239-4663 (international). Please dial into the call at least ten minutes prior to the start for the operator to connect you. The Conference ID is 9895268.
- Market Realist•3 days ago
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price. The stock has maintained growth momentum over the last year.
Markit•5 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Market Realist•9 days ago
Analyzing uniQure’s Valuation Trend
Its net loss per share was $0.83 in the second quarter of 2017. Of the ten analysts covering uniQure in September, three have given the stock a “strong buy,” and seven have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $49.56, implying an upside potential of 20.1% over uniQure’s closing price of $41.25 on September 13. In comparison, peers Baxter International (BAX), Sanofi (SNY), and Shire (SHPG) have mean ratings of 2.31, 1.8, and 1.83, respectively, and target prices of $79.62, $48.67, and $201.82, respectively.
- Business Wire•10 days ago
Baxter Named to Dow Jones Sustainability Index for 19th Consecutive Year, Recognized for Its Dedication to Corporate Responsibility
Baxter International Inc. (BAX), a leading global medical products company, today announced that it has been named to the Dow Jones Sustainability World Index (DJSI World Index) and the Dow Jones Sustainability North America Index (DJSI North America) for the 19th consecutive year. Baxter was recognized this year for its industry-leading performance in the following categories: policy influence, marketing practices, environmental reporting, human rights and occupational health and safety.
Markit•10 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Zacks•16 days ago
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
GuruFocus.com•17 days agoMS Global Franchise Fund Buys 1, Sells 4 in 2nd Quarter
Fund invests in Baxter International
- Zacks•17 days ago
Kidney Care Demand Shoots Up in US: 3 Stocks Likely to Gain
As the U.S. dialysis industry has been garnering huge profits for decades, some dialysis stocks are worth a look.
- Business Wire•17 days ago
Baxter Announces U.S. FDA Clearance of New Bone Graft Substitute, Actifuse Flow
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, today announced U.S. Food and Drug Administration (FDA) clearance of Actifuse Flow Bone Graft Substitute for use in a variety of orthopedic surgical procedures. As the newest addition to Baxter’s growing osteobiologics surgery portfolio, Actifuse Flow offers accelerated bone growth in a new, easy-to-use, prepackaged delivery syringe for precise placement into small bony voids or gaps in the skeletal system. Actifuse Flow utilizes the proprietary silicate-substituted technology of Baxter’s Actifuse Bone Graft Substitute, which enhances silicon levels to accelerate bone formation1.
- Zacks•19 days ago
Here's Why You Should Hold On to Baxter (BAX) Stock Now
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
- Business Wire•19 days ago
Baxter Unveils Olimel 7.6% High Protein Parenteral Nutrition Formulation at the 2018 ESPEN Congress
DEERFIELD, Ill.-- -- Highest protein and lowest glucose formulation among Parenteral Nutrition products, available in a standardized, triple-chamber bag 1,2,3,4 New PN formulation will help meet needs of high stress patients who require more protein and are often impacted by hyperglycemia OLIMEL 7.6% is the latest addition to Baxter’s olive oil-based parenteral nutrition portfolio Currently approved ...
Markit•20 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Simply Wall St.•26 days ago
Does Baxter International Inc’s (NYSE:BAX) PE Ratio Signal A Selling Opportunity?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
Markit•26 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
Markit•27 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
Market Realist•last monthMDT’s Minimally Invasive Therapies’ Fiscal Q1 2019 Performances
In the first quarter of fiscal 2019, Medtronic’s (MDT) Minimally Invasive Therapies Group reported revenue of $2.1 billion compared to $2.5 billion in the fiscal first quarter of 2018, reflecting a ~17% YoY (year-over-year) fall.
Market Realist•last monthWhat Does Baxter International’s Valuation Trend Indicate?
In 2012, Baxter International (BAX) adopted a $2 billion share buyback program. In November 2016 and February 2018, the company increased the program by $1.5 billion each.
Market Realist•last monthAnalyzing Baxter International’s Operational Performance
Sales from Baxter International’s (BAX) advanced surgery business, which includes biological products and medical devices that are used in surgical procedures, increased from $178 million in the second quarter of 2017 to $204 million in the second quarter of 2018. The marketing and administrative expenses incurred by Baxter International increased from $630 million in the second quarter of 2017 to $681 million in the second quarter of 2018.
Market Realist•last monthBaxter’s Global Business Units Continue to Deliver
Baxter International’s (BAX) global business units delivered strong performances in the second quarter.
Market Realist•last monthAnalyzing Baxter International’s Top Line Trends
Baxter International’s (BAX) global business units include renal care, medication delivery, pharmaceuticals, nutrition, advanced surgery, acute therapies, and other, which primarily includes sales from Baxter’s pharmaceutical partnering business. Baxter International generated revenue of $2.84 billion in the second quarter compared to $2.6 billion in the comparable period in 2017. Baxter International incurred a cost of sales of $1.6 billion in the second quarter compared to $1.47 billion in the second quarter of 2017.
Markit•last monthSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- GlobeNewswire•2 months ago
Recent Analysis Shows Washington Real Estate Investment Trust, FirstEnergy, Alexion Pharmaceuticals, Alaska Air Group, Fortune Brands Home & Security, and Baxter International Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Washington ...
